New! Polyclonal Antibodies to Canine CRP: marker of systemic inflammation

4 Sep, 2020


no comments

In dogs, C-reactive protein (CRP) can be used as a marker of inflammation. Its concentration in blood increases rapidly in systemic inflammation and decreases quickly during recovery. It has been shown to increase in disorders such as bacterial infections, sepsis and pyometra, as well as in the case of post-surgical infections. The marker responds to inflammatory stimuli more rapidly than white blood cells thus often giving more accurate information about the stage of infection. In several countries especially in Europe and Asia, canine CRP has become an established marker routinely used by veterinarians.

We have now expanded our canine CRP product offering to include polyclonal antibodies and provide monoclonal and polyclonal antibodies as well as a recombinant cCRP antigen – a full range of reagents for developing quantitative cCRP immunoassays.

Prototype assay using pAbs as a capture antibody and MAb cCRP1 as a detection antibody is suitable for the detection of native canine CRP in dog serum, see Figure 1.

Figure 1. cCRP concentration measured in serum of healthy dogs or dogs with systemic inflammation with two sandwich immunoassays, the other one (red bars) using pAbs as capture antibody. Detection antibody cCRP1cc was labelled with Eu3+.

Learn more:



Polyclonal Anti-canine C-reactive Protein (cCRP)

Canine C-reactive Protein (cCRP), monoclonal antibody

Recombinant canine C-reactive Protein (cCRP)

Advanced ImmunoChemical is open and business continues as normal

We confirm that we are continuing to supply our products as normal and do not foresee any significant disruption in product availability or ship schedules. However, circumstances can change. Please know we will continue to follow developments and do our best to advise you as soon as possible if the situation regarding our product supply changes.

Browse our products and order online at:

If you are interested in receiving further information or have other questions, please contact us by e-mail at
Skip to toolbar